Trial site
Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio Fatebenefratelli
Brescia, 25125, ItalyNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 2/33 trials
- Phase 33 trials
- Phase 22 trials
- Phase 1/21 trial
- Status
- Recruiting5 trials
- Active, not recruiting2 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
- AriBio Co., Ltd.1 trial
- Exciva GmbH1 trial
- Merck Sharp & Dohme LLC1 trial
- NSC-Therapeutics1 trial
- and 3 more
Running trials
Recruiting
A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer’s Disease Caused by a Genetic Mutation
2024-517187-36-01· Phase 2/3· Washington University School Of Medicine· Source
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472· Phase 2/3· Exciva GmbH· Source
Recruiting
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
NCT06995573· Phase 1/2· NSC-Therapeutics· Source
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Active, not recruiting
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· Phase 3· AriBio Co., Ltd.· Source
Not yet recruiting
Targeting inflammation in depression using Minocycline: a patient stratification approach using peripheral inflammatory biomarkers and MRI
NCT06207760· Phase 2· Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio Fatebenefratelli· Source
Active, not recruiting
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005· Phase 2/3· Washington University School of Medicine· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error